Last reviewed · How we verify
Ropivacaine 0.2% for L-ESPB
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Regional anesthesia via lateral erector spinae plane block for thoracic and abdominal wall anesthesia.
At a glance
| Generic name | Ropivacaine 0.2% for L-ESPB |
|---|---|
| Sponsor | Poznan University of Medical Sciences |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. This prevents depolarization and action potential generation in sensory and motor nerves. When administered via L-ESPB (Lateral Erector Spinae Plane Block), it provides regional anesthesia to the thoracic and abdominal wall by blocking nerve conduction in the relevant dermatomes.
Approved indications
- Regional anesthesia via lateral erector spinae plane block for thoracic and abdominal wall anesthesia
Common side effects
- Systemic toxicity (CNS effects: dizziness, tinnitus, seizures)
- Cardiovascular effects (hypotension, bradycardia)
- Local tissue irritation or infection at injection site
- Transient nerve injury
Key clinical trials
- PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery (NA)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
- PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.2% for L-ESPB CI brief — competitive landscape report
- Ropivacaine 0.2% for L-ESPB updates RSS · CI watch RSS
- Poznan University of Medical Sciences portfolio CI